References
- Finn, O J. Cancer vaccines: between the idea and the reality.Nat. Rev., Immunol. 2003, 3 (8), 630–641.
- Kern, D E.; Klarnet, J P.; Jensen, M C.; Greenberg, P D. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.J. Immunol. 1986, 136 (11), 4303–4310. [PUBMED], [INFOTRIEVE], [CSA]
- Ostrand-Rosenberg, S.; Thakur, A.; Clements, V. Rejection of mouse sarcoma cells after transfection of MHC class II genes.J. Immunol. 1990, 144 (10), 4068–4071. [PUBMED], [INFOTRIEVE], [CSA]
- Ossendorp, F.; Mengede, E.; Camps, M.; Filius, R.; Melief, C J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.J. Exp. Med. 1998, 187 (5), 693–702. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wang, J C.; Livingstone, A M. Cutting edge: CD4 + T cell help can be essential for primary CD8 + T cell responses in vivo.J. Immunol. 2003, 171 (12), 6339–6343. [PUBMED], [INFOTRIEVE], [CSA]
- Zajac, A J.; Murali-Krishna, K.; Blattman, J N.; Ahmed, R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4 + and CD8 + T cells.Curr. Opin. Immunol. 1998, 10 (4), 444–449. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gao, F G.; Khammanivong, V.; Liu, W J.; Leggatt, G R.; Frazer, I H.; Fernando, G J. Antigen-specific CD4 + T-cell help is required to activate a memory CD8 + T cell to a fully functional tumor killer cell.Cancer Res. 2002, 62 (22), 6438–6441. [PUBMED], [INFOTRIEVE], [CSA]
- Grakoui, A.; Shoukry, N H.; Woollard, D J.; Han, J H.; Hanson, H L.; Ghrayeb, J.; Murthy, K K.; Rice, C M.; Walker, C M. HCV persistence and immune evasion in the absence of memory T cell help.Science 2003, 302 (5645), 659–662. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Janssen, E M.; Lemmens, E E.; Wolfe, T.; Christen, U.; von Herrath, M G.; Schoenberger, S P. CD4 + T cells are required for secondary expansion and memory in CD8 + T lymphocytes.Nature 2003, 421 (6925), 852–856. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shedlock, D J.; Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory.Science 2003, 300 (5617), 337–339. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Constant, S L.; Bottomly, K. Induction of Th1 and Th2 CD4 + T cell responses: the alternative approaches.Annu. Rev. Immunol. 1997, 15, 297–322. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shurin, M R.; Lu, L.; Kalinski, P.; Stewart-Akers, A M.; Lotze, M T. Th1/Th2 balance in cancer, transplantation and pregnancy.Springer Semin. Immunopathol. 1999, 21 (3), 339–359. [PUBMED], [INFOTRIEVE], [CSA]
- Mosmann, T R.; Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more.Immunol. Today 1996, 17 (3), 138–146. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Qin, Z.; Richter, G.; Schuler, T.; Ibe, S.; Cao, X.; Blankenstein, T. B cells inhibit induction of T cell-dependent tumor immunity.Nat. Med. 1998, 4 (5), 627–630. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tatsumi, T.; Kierstead, L S.; Ranieri, E.; Gesualdo, L.; Schena, F P.; , et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.J. Exp. Med. 2002, 196 (5), 619–628. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ostrand-Rosenberg, S.; Grusby, M J.; Clements, V K. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.J. Immunol. 2000, 165 (11), 6015–6019. [PUBMED], [INFOTRIEVE], [CSA]
- Ostrand-Rosenberg, S.; Clements, V K.; Terabe, M.; Park, J M.; Berzofsky, J A.; Dissanayake, S K. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.J. Immunol. 2002, 169 (10), 5796–5804. [PUBMED], [INFOTRIEVE], [CSA]
- Terabe, M.; Matsui, S.; Noben-Trauth, N.; Chen, H.; Watson, C.; , et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.Nat. Immunol. 2000, 1 (6), 515–520. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kacha, A K.; Fallarino, F.; Markiewicz, M A.; Gajewski, T F. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.J. Immunol. 2000, 165 (11), 6024–6028. [PUBMED], [INFOTRIEVE], [CSA]
- Vogel, C.; Cobleigh, M A.; Tripathy, D.; Gutheil, J C.; Harris, L N.; , et al. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.Eur. J. Cancer 2001, 37 (Suppl. 1), 25–29. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hsu, F J.; Caspar, C B.; Czerwinski, D.; Kwak, L W.; Liles, T M.; , et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial.Blood 1997, 89 (9), 3129–3135. [PUBMED], [INFOTRIEVE], [CSA]
- Mattes, J.; Hulett, M.; Xie, W.; Hogan, S.; Rothenberg, M E.; , et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process.J. Exp. Med. 2003, 197 (3), 387–393. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nishimura, T.; Iwakabe, K.; Sekimoto, M.; Ohmi, Y.; , et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.J. Exp. Med. 1999, 190 (5), 617–627. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Golumbek, P T.; Lazenby, A J.; Levitsky, H I.; Jaffee, L M.; Karasuyama, H.; Baker, M.; Pardoll, D M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.Science 1991, 254 (5032), 713–716. [PUBMED], [INFOTRIEVE], [CSA]
- Bennett, S R.; Carbone, F R.; Karamalis, F.; Miller, J F.; Heath, W R. Induction of a CD8 + cytotoxic T lymphocyte response by cross-priming requires cognate CD4 + T cell help.J. Exp. Med. 1997, 186 (1), 65–70. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Keene, J A.; Forman, J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.J. Exp. Med. 1982, 155 (3), 768–782. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ridge, J P.; Di Rosa, F.; Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4 + T-helper and a T-killer cell.Nature 1998, 393 (6684), 474–478. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schoenberger, S P.; Toes, R E.; van der Voort, E I.; Offringa, R.; Melief, C J. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions.Nature 1998, 393 (6684), 480–483. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bennett, S R.; Carbone, F R.; Karamalis, F.; Flavell, R A.; Miller, J F.; Heath, W R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling.Nature 1998, 393 (6684), 478–480. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hung, K.; Hayashi, R.; Lafond-Walker, A.; Lowenstein, C.; Pardoll, D.; Levitsky, H. The central role of CD4(+) T cells in the antitumor immune response.J. Exp. Med. 1998, 188 (12), 2357–2368. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pulaski, B A.; Smyth, M J.; Ostrand-Rosenberg, S. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma.Cancer Res. 2002, 62 (15), 4406–4412. [PUBMED], [INFOTRIEVE], [CSA]
- Mumberg, D.; Monach, P A.; Wanderling, S.; Philip, M.; Toledano, A Y.; Schreiber, R D.; Schreiber, H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (15), 8633–8638. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Beatty, G.; Paterson, Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4 + T cells requires tumor responsiveness to IFN-gamma.J. Immunol. 2001, 166 (4), 2276–2282. [PUBMED], [INFOTRIEVE], [CSA]
- Wang, R F.; Wang, X.; Atwood, A C.; Topalian, S L.; Rosenberg, S A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.Science 1999, 284 (5418), 1351–1354. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pieper, R.; Christian, R E.; Gonzales, M I.; Nishimura, M I.; Gupta, G.; , et al. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.J. Exp. Med. 1999, 189 (5), 757–766. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Topalian, S L.; Gonzales, M I.; Parkhurst, M.; Li, Y F.; Southwood, S.; , et al. Melanoma-specific CD4 + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.J. Exp. Med. 1996, 183 (5), 1965–1971. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zarour, H M.; Storkus, W J.; Brusic, V.; Williams, E.; Kirkwood, J M. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4 + T cells.Cancer Res. 2000, 60 (17), 4946–4952. [PUBMED], [INFOTRIEVE], [CSA]
- Zarour, H M.; Maillere, B.; Brusic, V.; Coval, K.; Williams, E.; , et al. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4 + T cells.Cancer Res. 2002, 62 (1), 213–218. [PUBMED], [INFOTRIEVE], [CSA]
- Mandic, M.; Almunia, C.; Vicel, S.; Gillet, D.; Janjic, B.; , et al. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4 + T cells.Cancer Res. 2003, 63 (19), 6506–6515. [PUBMED], [INFOTRIEVE], [CSA]
- Zarour, H M.; Kirkwood, J M.; Kierstead, L S.; Herr, W.; Brusic, V.; , et al. Melan-A/MART-1(51–73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.Proc. Natl. Acad. Sci. U. S. A. 2000, 97 (1), 400–405. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ranieri, E.; Kierstead, L S.; Zarour, H.; Kirkwood, J M.; Lotze, M T.; Whiteside, T.; Storkus, W J. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading.Immunol. Invest. 2000, 29 (2), 121–125. [PUBMED], [INFOTRIEVE], [CSA]
- Zarour, H M.; Kirkwood, J M. Melanoma vaccines: early progress and future promises.Semin. Cutan. Med. Surg. 2003, 22 (1), 68–75. [PUBMED], [INFOTRIEVE], [CSA]
- Nestle, F O.; Alijagic, S.; Gilliet, M.; Sun, Y.; , et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.Nat. Med. 1998, 4 (3), 328–332. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vermij, P.; Frei, M. Halted trial renews questions about cancer vaccines.Nat. Med. 2004, 10 (1), 3. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Armstrong, T D.; Clements, V K.; Ostrand-Rosenberg, S. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4 + T lymphocytes.J. Immunol. 1998, 160 (2), 661–666. [PUBMED], [INFOTRIEVE], [CSA]
- Armstrong, T D.; Clements, V K.; Martin, B K.; Ting, J P.; Ostrand-Rosenberg, S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.Proc. Natl. Acad. Sci. U. S. A. 1997, 94 (13), 6886–6891. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Qi, L.; Rojas, J M.; Ostrand-Rosenberg, S. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo.J. Immunol. 2000, 165 (10), 5451–5461. [PUBMED], [INFOTRIEVE], [CSA]
- Ostrand-Rosenberg, S.; Baskar, S.; Patterson, N.; Clements, V K. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.Tissue Antigens 1996, 47 (5), 414–421. [PUBMED], [INFOTRIEVE], [CSA]
- Pulaski, B A.; Ostrand-Rosenberg, S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.Cancer Res. 1998, 58 (7), 1486–1493. [PUBMED], [INFOTRIEVE], [CSA]
- Baskar, S.; Ostrand-Rosenberg, S.; Nabavi, N.; Nadler, L M.; Freeman, G J.; Glimcher, L H. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.Proc. Natl. Acad. Sci. U. S. A. 1993, 90 (12), 5687–5690. [PUBMED], [INFOTRIEVE], [CSA]
- Baskar, S.; Glimcher, L.; Nabavi, N.; Jones, R T.; Ostrand-Rosenberg, S. Major histocompatibility complex class II + B7-1 + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.J. Exp. Med. 1995, 181 (2), 619–629. [PUBMED], [INFOTRIEVE], [CSA]
- Clements, V K.; Baskar, S.; Armstrong, T D.; Ostrand-Rosenberg, S. Invariant chain alters the malignant phenotype of MHC class II + tumor cells.J. Immunol. 1992, 149 (7), 2391–2396. [PUBMED], [INFOTRIEVE], [CSA]
- Qi, L.; Ostrand-Rosenberg, S. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.Traffic 2000, 1 (2), 152–160. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lu, X.; Kallinteris, N L.; Li, J.; Wu, S.; Li, Y.; , et al. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype.Cancer Immunol. Immunother. 2003, 52 (10), 592–598. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hillman, G G.; Kallinteris, N L.; Li, J.; Wang, Y.; Lu, X.; , et al. Generating MHC class II + /Ii − phenotype after adenoviral delivery of both an expressible gene for MHC class II inducer and an antisense Ii-RNA construct in tumor cells.Gene Ther. 2003, 10 (17), 1512–1518. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zhao, Y.; Boczkowski, D.; Nair, S K.; Gilboa, E. Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4 + T-cell responses and tumor immunity.Blood 2003, 102 (12), 4137–4142. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ji, H.; Wang, T L.; Chen, C H.; Pai, S I.; Hung, C F.; , et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.Hum. Gene Ther. 1999, 10 (17), 2727–2740. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ji, H.; Chang, E Y.; Lin, K Y.; Kurman, R J.; Pardoll, D M.; Wu, T C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein.Int. J. Cancer 1998, 78 (1), 41–45. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wu, T C.; Guarnieri, F G.; Staveley-O'Carroll, K F.; Viscidi, R P.; Levitsky, H I.; , et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.Proc. Natl. Acad. Sci. U. S. A. 1995, 92 (25), 11671–11675. [PUBMED], [INFOTRIEVE], [CSA]
- Wang, R F.; Wang, X.; Rosenberg, S A. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.J. Exp. Med. 1999, 189 (10), 1659–1668. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hock, H.; Dorsch, M.; Richter, G.; Kunzendorf, U.; , et al. Tumor-cell-targeted cytokine gene transfer in experimental models for cancer therapy.Nat. Immun. 1994, 13 (2–3), 85–92. [PUBMED], [INFOTRIEVE], [CSA]
- Takahashi, T.; Tagami, T.; Yamazaki, S.; Uede, T.; Shimizu, J.; , et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.J. Exp. Med. 2000, 192 (2), 303–310. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Read, S.; Malmstrom, V.; Powrie, F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.J. Exp. Med. 2000, 192 (2), 295–302. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Caramalho, I.; Lopes-Carvalho, T.; Ostler, D.; Zelenay, S.; , et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide.J. Exp. Med. 2003, 197 (4), 403–411. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- McHugh, R S.; Whitters, M J.; Piccirillo, C A.; Young, D A.; Shevach, E M.; Collins, M.; Byrne, M C. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.Immunity 2002, 16 (2), 311–323. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fontenot, J D.; Gavin, M A.; Rudensky, A Y. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells.Nat. Immunol. 2003, 4 (4), 330–336. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3.Science 2003, 299 (5609), 1057–1061. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Khattri, R.; Cox, T.; Yasayko, S A.; Ramsdell, F. An essential role for Scurfin in CD4 + CD25 + T regulatory cells.Nat. Immunol. 2003, 4 (4), 337–342. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M.; Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J. Immunol. 1995, 155 (3), 1151–1164. [PUBMED], [INFOTRIEVE], [CSA]
- Sakaguchi, S.; Sakaguchi, N.; Shimizu, J.; Yamazaki, S.; Sakihama, T.; , et al. Immunologic tolerance maintained by CD25 + CD4 + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.Immunol. Rev. 2001, 182, 18–32.. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shevach, E M. Certified professionals: CD4(+)CD25(+) suppressor T cells.J. Exp. Med. 2001, 193 (11), F41–F46. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shimizu, J.; Yamazaki, S.; Sakaguchi, S. Induction of tumor immunity by removing CD25 + CD4 + T cells: a common basis between tumor immunity and autoimmunity.J. Immunol. 1999, 163 (10), 5211–5218. [PUBMED], [INFOTRIEVE], [CSA]
- Onizuka, S.; Tawara, I.; Shimizu, J.; Sakaguchi, S.; Fujita, T.; Nakayama, E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.Cancer Res. 1999, 59 (13), 3128–3133. [PUBMED], [INFOTRIEVE], [CSA]
- Sutmuller, R P.; van Duivenvoorde, L M.; van Elsas, A.; Schumacher, T N.; Wildenberg, M E.; , et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.J. Exp. Med. 2001, 194 (6), 823–832. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Woo, E Y.; Yeh, H.; Chu, C S.; Schlienger, K.; Carroll, R G.; , et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.J. Immunol. 2002, 168 (9), 4272–4276. [PUBMED], [INFOTRIEVE], [CSA]
- Liyanage, U K.; Moore, T T.; Joo, H G.; Tanaka, Y.; Herrmann, V.; , et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.J. Immunol. 2002, 169 (5), 2756–2761. [PUBMED], [INFOTRIEVE], [CSA]
- Suri-Payer, E.; Amar, A Z.; Thornton, A M.; Shevach, E M. CD4 + CD25 + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.J. Immunol. 1998, 160 (3), 1212–1218. [PUBMED], [INFOTRIEVE], [CSA]
- Suri-Payer, E.; Amar, A Z.; McHugh, R.; Natarajan, K.; Margulies, D H.; Shevach, E M. Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells.Eur. J. Immunol. 1999, 29 (2), 669–677. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Azuma, T.; Takahashi, T.; Kunisato, A.; Kitamura, T.; Hirai, H. Human CD4 + CD25 + regulatory T cells suppress NKT cell functions.Cancer Res. 2003, 63 (15), 4516–4520. [PUBMED], [INFOTRIEVE], [CSA]
- Thornton, A M.; Shevach, E M. CD4 + CD25 + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.J. Exp. Med. 1998, 188 (2), 287–296. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Takahashi, T.; Kuniyasu, Y.; Toda, M.; Sakaguchi, N.; Itoh, M.; Iwata, M.; Shimizu, J.; Sakaguchi, S. Immunologic self-tolerance maintained by CD25 + CD4 + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.Int. Immunol. 1998, 10 (12), 1969–1980. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]